In addition to EGFR inhibitors, targeted agents that have been shown to trigger AKI are BRAF blockers [124,125], B-cell lymphoma-2 inhibitors [126], and BCR-ABL1 and receptor tyrosine kinase inhibitor [127,128,129]. This evidence concerns the gene EGFR and acute kidney injury.